基于风险适应性辅助治疗的绝经后早期乳腺癌患者结局:丹麦乳腺癌协作组全国性前瞻性队列研究
这项全国性前瞻性队列研究纳入8921例绝经后雌激素受体阳性、HER2阴性早期乳腺癌患者,按预后标准死亡率指数(PSI)分组并给予风险适应性辅助治疗。PSI 1组推荐5年内分泌治疗,PSI 2-4组推荐内分泌联合辅助化疗。PSI 1组粗标准死亡比为0.89,PSI 2为1.71,PSI 3-4为2.39。
要点
- PSI 1组推荐5年内分泌治疗,未化疗与总体超额死亡无关联。
- PSI 2-4组推荐内分泌联合辅助化疗,PSI 3-4组完成治疗后仍有较高超额死亡。
- 完成内分泌治疗者PSI 1组结局优于未完成者。
核心结论
- 数据验证了PSI工具用于风险适应性治疗分配的临床价值。
- PSI 1患者省略化疗与总体超额死亡无关联,完成内分泌治疗者结局优于未完成者。
- 完成辅助治疗后PSI 2患者超额死亡低,PSI 3-4患者超额死亡高,可能需强化治疗并需进一步研究。
研究设计与样本
- 丹麦乳腺癌协作组(DBCG)开展的全国性前瞻性队列研究。
- 纳入2013年8月1日至2018年12月31日确诊并登记于DBCG临床数据库的50岁及以上绝经后丹麦女性。
- 纳入条件为浸润性雌激素受体阳性、HER2阴性且已切除的乳腺癌,共8921例符合条件并分配PSI类别。
- PSI 1组6704例(75%),PSI 2组1300例(15%),PSI 3组745例(8%),PSI 4组172例(2%)。
- PSI 1组推荐5年内分泌治疗;PSI 2、3或4组按丹麦国家指南推荐内分泌治疗联合辅助化疗。
主要发现
- 8830例中8514例(96%)启动内分泌治疗,91例治疗状态未知。
- 4.5年依从率PSI 1组为67.8%(66.6-69.0),PSI 2-4组为72.3%(70.5-74.3)。
- 粗标准死亡比PSI 1组为0.89(95%CI 0.85-0.95),PSI 2组为1.71(95%CI 1.47-1.97),PSI 3-4组为2.39(95%CI 1.99-2.88)。
- 与完成辅助治疗的PSI 1患者相比,PSI 2患者超额死亡相对风险(RR)为1.33(95%CI 1.01-1.76)。
- 与完成辅助治疗的PSI 1患者相比,PSI 3-4患者完成治疗后仍保留超额死亡(RR 2.31,95%CI 1.74-3.05)。
关键数值与推荐
- PSI 1组推荐5年内分泌治疗。
- PSI 2、3或4组按丹麦国家指南推荐内分泌治疗联合辅助化疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- PSI 3-4患者超额死亡高可能需强化治疗,但原文指出这需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical prediction models are increasingly used to guide treatment in patients with early breast cancer. The Danish Breast Cancer Group (DBCG) has developed a prognostic standard mortality rate index (PSI) for prediction of excess mortality based on 5 years of endocrine therapy. In this study, we aimed to evaluate the clinical utility of the PSI. METHODS: In this nationwide, prospective cohort study, we included postmenopausal Danish women aged 50 years or older with invasive oestrogen receptor-positive and HER2-negative resected breast cancer registered in the DBCG clinical database (close to all Danish women newly diagnosed with invasive breast cancer are registered in the national database). All participants were assigned a PSI category. Patients in the PSI 1 category were recommended 5 years of endocrine therapy; patients in PSI 2, 3, or 4 category were recommended endocrine therapy plus adjuvant chemotherapy according to Danish national guidelines. The primary endpoint was standard mortality ratio. Univariable and multivariable analyses for standard mortality ratio, overall survival, and recurrence-free survival were performed applying Kaplan-Meier, cumulative incidence, Poisson regression, and Fine-Gray subdistribution hazards model. FINDINGS: 25 027 women diagnosed with breast cancer between Aug 1, 2013, and Dec 31, 2018, and registered with the DBCG clinical database were identified. 8921 of those registered were eligible, assigned a PSI category (6704 [75%] PSI 1, 1300 [15%] PSI 2, 745 [8%] PSI 3, and 172 [2%] PSI 4), and included in the study. 8514 [96%] of 8830 women initiated endocrine therapy and 91 had an unknown therapy status. Adherence at 4·5 years was 67·8% (66·6-69·0) in the PSI 1 group and 72·3% (70·5-74·3) in the PSI 2-4 groups. Crude standard mortality ratio was 0·89 (95% CI 0·85-0·95) with PSI 1, 1·71 (95% CI 1·47-1·97) with PSI 2, and 2·39 (95% CI 1·99-2·88) with PSI 3-4. Compared with patients who completed adjuvant therapy with PSI 1, relative risk (RR) for excess mortality was 1·33 (95% CI 1·01-1·76) for patients with PSI 2 whereas patients with PSI 3-4 retained an excess mortality (RR 2·31, 95% CI 1·74-3·05) even with completed therapy. INTERPRETATION: These data validate the clinical use of the PSI tool for risk adapted treatment allocation. In patients with PSI 1, the omission of chemotherapy was not associated with excess mortality overall and a distinct better outcome was seen in patients with completed endocrine therapy versus those who had not completed. With completed adjuvant therapy, excess mortality was low for patients with PSI 2, whereas patients with PSI 3-4 had high excess mortality, potentially warranting intensified treatment and requiring further investigation. FUNDING: None.
引用
- Jensen MB, Torpe E, Teunissen Z, et al. Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group. Lancet Oncol. 2025. PMID: 40318647. doi:10.1016/S1470-2045(25)00085-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。